In a statement, Dr. Sanjeewa claimed that decisions taken by the Authority in sourcing specific ophthalmic drugs could compromise patient safety, particularly for those undergoing eye surgeries.
He pointed out that medicines administered before and after surgical procedures must meet stringent quality standards. According to him, non-medicinal additional components — known as “free particles” — should either be completely absent or maintained at minimal levels to prevent complications.
However, he alleged that some of the recently procured drugs contain levels that exceed the limits recommended by eye surgeons, casting doubt on their suitability for clinical use.
Dr. Sanjeewa further stated that ophthalmologists had formally conveyed their concerns to NMRA Chairman Dr. Ananda Wijewickrama, but claimed that adequate corrective action had not been taken.
Calling the situation regrettable, he urged the President to launch an immediate investigation into the matter and stressed that responsibility should rest with the NMRA Chairman if any adverse outcomes arise among patients as a result of the disputed medications.
